Reinhard E. Friedrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Reinhard E. Friedrich has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Rainer Schmelzle
4 shared publications- Max Heiland
Department of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
3 shared publications Sylva Bartel-Friedrich
Department of Otorhinolaryngology, Martin-Luther University, Halle a. d. S., Germany
3 shared publicationsC Lautenschläger
2 shared publicationsKarl Donath
2 shared publicationsM. Giese
Klinik für Mund-, Kiefer- und Gesichtschirurgie, Nordwestdeutsche Kieferklinik, Universitätsklinikum Hamburg-Eppendorf
2 shared publications
Latest Publications
- Open Access
- 29 November 2013
- Vol. 2
Ultrasonographically supported removal of foreign bodies of the eye lid and parapharyngeal space in a 13-year-old boy subjected to shot injuries in early childhood
Background: B-scan ultrasonography is widely used in diagnostics of head and neck pathologies. Ultrasonography can be applied intraoperatively to identify foreign materials.
- 29 November 2013
- Vol. 2
Open AccessUltrasonographically supported removal of foreign bodies of the eye lid and parapharyngeal space in a 13-year-old boy subjected to shot injuries in early childhood
Background: B-scan ultrasonography is widely used in diagnostics of head and neck pathologies. Ultrasonography can be applied intraoperatively to identify foreign materials.
- 26 July 2007
- Vol. 27, 2085-90
Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1.
Neurofibromatosis type 1 (NF1) is an autosomal-dominant inherited disease, characterised by the development of nerve sheath tumors. NF1 is the most frequently inherited disease associated with a predisposition for cancer (in particular malignant peripheral nerve sheath tumors: MPNST). NF1 is a progressive disease with phase-like growth spurts of dermal or plexiform neurofibroma (PNF). These tumors can cause severe disfigurement of patients. Growth control of these tumors is poorly understood. The aim of this study was to identify the expression of insulin-like growth factor 1-receptor (IGF-1R) in peripheral nerve sheath tumors. Factor and receptor are involved in the growth control of numerous physiological and pathological processes, including Schwann cell development. The investigation included tumors of NF1-patients only (neurofibroma, MPNST). Sections of the specimens were immunohistochemically typed for several antigens (target antigens: IGF-1R, S-100, EMA, CD34, MIB-1), using both single and double-staining methods. Double-staining allowed the sub-typing of the IGF-1R-expressing cells in the mixed nerve sheath tumors. The expression was also investigated in Schwann cell cultures and co-cultures with fibroblasts. Staining of S-100 and IGF-1R, PNF were more intensely marked than MPNST (r = -0.439, p < 0.002, N = 49). The proliferation index was tumor-type dependent: MPNST > neurofibroma. The IGF-1R-expression correlated positively with the MIB-1 index in neurofibroma (r = 0.372, p = 0.021, N = 38). The receptor expression was higher in PNF than in dermal neurofibroma (r = 0.335, p = 0.040, N = 38). IGF-1R was detected in Schwann cells (S-100 positive) and in perineurial cells (EMA-positive) of all nerve sheath tumors. However, the receptor was also identified in CD34-marked endothelia of neurofibromas but not in endothelia of MPNST. In Schwann cell cultures, a strong receptor-expression became evident. This expression was independent of co-cultivation of tumor cells with fibroblasts. The statistical calculations excluded the impact of gender on the receptor expression. This investigation provides evidence for the expression of IGF-1R in nerve sheath tumors in NF1. The expression pattern varied between the tumor types, the cell types, and between tumors of the same type. IGF and IGF-1R are a prerequisite to maintain Schwann cell stability in the postnatal period and to prevent Schwann cell apoptosis. The first evidence for IGF-1R expression in mutated Schwann cells may indicate a tumor-type associated receptor expression in NF1.
- 26 July 2007
- Vol. 27, 2085-90
Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1.
Neurofibromatosis type 1 (NF1) is an autosomal-dominant inherited disease, characterised by the development of nerve sheath tumors. NF1 is the most frequently inherited disease associated with a predisposition for cancer (in particular malignant peripheral nerve sheath tumors: MPNST). NF1 is a progressive disease with phase-like growth spurts of dermal or plexiform neurofibroma (PNF). These tumors can cause severe disfigurement of patients. Growth control of these tumors is poorly understood. The aim of this study was to identify the expression of insulin-like growth factor 1-receptor (IGF-1R) in peripheral nerve sheath tumors. Factor and receptor are involved in the growth control of numerous physiological and pathological processes, including Schwann cell development. The investigation included tumors of NF1-patients only (neurofibroma, MPNST). Sections of the specimens were immunohistochemically typed for several antigens (target antigens: IGF-1R, S-100, EMA, CD34, MIB-1), using both single and double-staining methods. Double-staining allowed the sub-typing of the IGF-1R-expressing cells in the mixed nerve sheath tumors. The expression was also investigated in Schwann cell cultures and co-cultures with fibroblasts. Staining of S-100 and IGF-1R, PNF were more intensely marked than MPNST (r = -0.439, p < 0.002, N = 49). The proliferation index was tumor-type dependent: MPNST > neurofibroma. The IGF-1R-expression correlated positively with the MIB-1 index in neurofibroma (r = 0.372, p = 0.021, N = 38). The receptor expression was higher in PNF than in dermal neurofibroma (r = 0.335, p = 0.040, N = 38). IGF-1R was detected in Schwann cells (S-100 positive) and in perineurial cells (EMA-positive) of all nerve sheath tumors. However, the receptor was also identified in CD34-marked endothelia of neurofibromas but not in endothelia of MPNST. In Schwann cell cultures, a strong receptor-expression became evident. This expression was independent of co-cultivation of tumor cells with fibroblasts. The statistical calculations excluded the impact of gender on the receptor expression. This investigation provides evidence for the expression of IGF-1R in nerve sheath tumors in NF1. The expression pattern varied between the tumor types, the cell types, and between tumors of the same type. IGF and IGF-1R are a prerequisite to maintain Schwann cell stability in the postnatal period and to prevent Schwann cell apoptosis. The first evidence for IGF-1R expression in mutated Schwann cells may indicate a tumor-type associated receptor expression in NF1.
- Open Access
- 1 January 2006
- Published by FapUNIFESP (SciELO) in Brazilian Dental Journal
- Vol. 17 (1) , 58-62
Toxicity screening of mouthwashes in the pollen tube growth test: safety assessment of recommended dilutions
This study investigated whether mouthwash dilutions, recommended by the manufacturers, may contribute to oral mucosa irritation. Twenty frequently used mouthwash brands were examined by the pollen tube growth test, an alternative in vitro method for assessment of the irritating potential of ingredients of cosmetic formulations. The test is based on the photometric quantification of pollen tube growth inhibition. This parameter is expressed by IC50 values that characterize the cytotoxic potential of a product. The IC50s clearly revealed that none of the tested mouthwashes should cause acute irritation if used in the recommended dilution. However, at least 4 of the mouthwashes evaluated in this study could probably irritate the oral mucosa acutely if used undiluted (original concentration).
- 1 January 2006
- Published by FapUNIFESP (SciELO) in Brazilian Dental Journal
- Vol. 17 (1) , 58-62
Open AccessToxicity screening of mouthwashes in the pollen tube growth test: safety assessment of recommended dilutions
This study investigated whether mouthwash dilutions, recommended by the manufacturers, may contribute to oral mucosa irritation. Twenty frequently used mouthwash brands were examined by the pollen tube growth test, an alternative in vitro method for assessment of the irritating potential of ingredients of cosmetic formulations. The test is based on the photometric quantification of pollen tube growth inhibition. This parameter is expressed by IC50 values that characterize the cytotoxic potential of a product. The IC50s clearly revealed that none of the tested mouthwashes should cause acute irritation if used in the recommended dilution. However, at least 4 of the mouthwashes evaluated in this study could probably irritate the oral mucosa acutely if used undiluted (original concentration).
- 22 July 2005
- Vol. 25, 1693-7
Diagnosis, treatment and follow-up control in 124 patients with basal cell carcinoma of the maxillofacial region treated from 1992 to 1997.
The aim of this study was to analyze diagnostic and therapeutic procedures and the outcome of patients treated for the most common malignant tumor of the facial skin, basal cell carcinoma. The files of patients with basal cell carcinoma (BCC) treated over a period of 6 years were evaluated. Emphasis was placed on the frequency of second interventions, local recurrences and histological subtyping of tumors. One-hundred and twenty-four patients were treated for 216 basal cell carcinomas (solitary: 67%, multiple: 33%). The tumors were predominantly located in the skin covering the middle third of the face. The tumors were 30 mm or less in diameter in 86%. Treatment was exclusively surgical. Histopathological subtyping revealed solid (83%), sclerodermiform (10%), metatypical (4%) and multicentric (3%) tumors. Resection of adjacent bone was mandatory in 12 patients and orbital exenteration in 2. Further local resections were necessary after thorough histological investigation in 71% of patients. Local recurrences occurred in 14 patients, predominantly within the first year after ablative surgery. Relative to the small number of sclerodermiform BCC, this subtype was the most frequent tumor that developed local recurrences. Basal cell carcinoma is a malignant tumor, slowly growing and often showing wide extension to macroscopically non-affected sites. Resection of tumors is delicate in the maxillofacial region due to the predilection for sites of origin adjacent to structures of eminent importance for facial appearance. The sclerodermiform subtype is prone to local recurrence and these patients should be followed up carefully.
- 22 July 2005
- Vol. 25, 1693-7
Diagnosis, treatment and follow-up control in 124 patients with basal cell carcinoma of the maxillofacial region treated from 1992 to 1997.
The aim of this study was to analyze diagnostic and therapeutic procedures and the outcome of patients treated for the most common malignant tumor of the facial skin, basal cell carcinoma. The files of patients with basal cell carcinoma (BCC) treated over a period of 6 years were evaluated. Emphasis was placed on the frequency of second interventions, local recurrences and histological subtyping of tumors. One-hundred and twenty-four patients were treated for 216 basal cell carcinomas (solitary: 67%, multiple: 33%). The tumors were predominantly located in the skin covering the middle third of the face. The tumors were 30 mm or less in diameter in 86%. Treatment was exclusively surgical. Histopathological subtyping revealed solid (83%), sclerodermiform (10%), metatypical (4%) and multicentric (3%) tumors. Resection of adjacent bone was mandatory in 12 patients and orbital exenteration in 2. Further local resections were necessary after thorough histological investigation in 71% of patients. Local recurrences occurred in 14 patients, predominantly within the first year after ablative surgery. Relative to the small number of sclerodermiform BCC, this subtype was the most frequent tumor that developed local recurrences. Basal cell carcinoma is a malignant tumor, slowly growing and often showing wide extension to macroscopically non-affected sites. Resection of tumors is delicate in the maxillofacial region due to the predilection for sites of origin adjacent to structures of eminent importance for facial appearance. The sclerodermiform subtype is prone to local recurrence and these patients should be followed up carefully.
- 22 July 2005
- Vol. 25, 1699-702
Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
Plexiform neurofibroma (PNF) is a typical feature of neurofibromatosis 1 (NF1). About 10% of patients with NF1 develop malignant peripheral nerve sheath tumors (MPNST), usually arising from PNF, and this is the major cause of poor prognosis. A better prognosis can be achieved if the tumors are diagnosed at an early stage. Our objective was to establish magnetic resonance imaging (MRI) criteria for MPNST, and to test their usefulness in detecting early malignant changes in PNF and to correlate the findings with the mutations of the NF1 gene. NF1 outpatients were diagnosed according to the NIH criteria. All patients underwent a complete dermatological, ophthalmological and neurological examination and ultrasound of the abdomen between 1997 and 2002. The study was approved by the Institutional Review Board and all patients gave informed consent to analyze clinical records and tumor material for scientific purposes. MRI was performed with devices at 1.5 Tesla field strength (Siemens Magnetom Symphony) or in some patients at 1.0 Tesla field strength (Siemens Impact Expert). T1- and T2-weighted sequences including STIR-sequences were acquired. Ultra-rapid image sequences with HASTE technique were performed for trunk imaging. In patients with no contraindication for the application of contrast media, Gadolinum-DTPA Magnevist was administered intravenously. MRI was performed on 50 patients with NF1 and nerve sheath tumors, of whom 7 had atypical pain, tumor growth or neurological deficits indicative of malignancy; the other 43 were asymptomatic. On MRI, all 7 symptomatic patients had inhomogeneous lesions, due to necrosis and hemorrhage and patchy contrast enhancement. In one patient, the multiplicity of confluent tumors with inhomogeneous areas in addition to central lesions did not allow the exclusion of malignancy. Only 3 of the 43 asymptomatic patients had comparable changes; the other 40 patients had tumors of relatively homogeneous structure on T1- and T2-weighted images before and after contrast enhancement. All 3 asymptomatic patients with inhomogeneous lesions were shown to have MPNST. Analysis of mutations of the NF1 gene of the 10 MPNST patients revealed a variety of mutations. Concerning the correlation of genetic findings and MPNST in NF1, the sample size of this study group was too small to define genotype-phenotype relations. In this cohort, all types of mutations were found. This study provides evidence for certain radiographic findings on MRI in PNF of NF1 patients that have to be considered as signs of malignancy, in particular indicating an MPNST. These findings are especially valuable in the long term follow-up control of patients with large tumors (plexiform neurofibromas).
- 22 July 2005
- Vol. 25, 1699-702
Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
Plexiform neurofibroma (PNF) is a typical feature of neurofibromatosis 1 (NF1). About 10% of patients with NF1 develop malignant peripheral nerve sheath tumors (MPNST), usually arising from PNF, and this is the major cause of poor prognosis. A better prognosis can be achieved if the tumors are diagnosed at an early stage. Our objective was to establish magnetic resonance imaging (MRI) criteria for MPNST, and to test their usefulness in detecting early malignant changes in PNF and to correlate the findings with the mutations of the NF1 gene. NF1 outpatients were diagnosed according to the NIH criteria. All patients underwent a complete dermatological, ophthalmological and neurological examination and ultrasound of the abdomen between 1997 and 2002. The study was approved by the Institutional Review Board and all patients gave informed consent to analyze clinical records and tumor material for scientific purposes. MRI was performed with devices at 1.5 Tesla field strength (Siemens Magnetom Symphony) or in some patients at 1.0 Tesla field strength (Siemens Impact Expert). T1- and T2-weighted sequences including STIR-sequences were acquired. Ultra-rapid image sequences with HASTE technique were performed for trunk imaging. In patients with no contraindication for the application of contrast media, Gadolinum-DTPA Magnevist was administered intravenously. MRI was performed on 50 patients with NF1 and nerve sheath tumors, of whom 7 had atypical pain, tumor growth or neurological deficits indicative of malignancy; the other 43 were asymptomatic. On MRI, all 7 symptomatic patients had inhomogeneous lesions, due to necrosis and hemorrhage and patchy contrast enhancement. In one patient, the multiplicity of confluent tumors with inhomogeneous areas in addition to central lesions did not allow the exclusion of malignancy. Only 3 of the 43 asymptomatic patients had comparable changes; the other 40 patients had tumors of relatively homogeneous structure on T1- and T2-weighted images before and after contrast enhancement. All 3 asymptomatic patients with inhomogeneous lesions were shown to have MPNST. Analysis of mutations of the NF1 gene of the 10 MPNST patients revealed a variety of mutations. Concerning the correlation of genetic findings and MPNST in NF1, the sample size of this study group was too small to define genotype-phenotype relations. In this cohort, all types of mutations were found. This study provides evidence for certain radiographic findings on MRI in PNF of NF1 patients that have to be considered as signs of malignancy, in particular indicating an MPNST. These findings are especially valuable in the long term follow-up control of patients with large tumors (plexiform neurofibromas).
- 22 July 2005
- Vol. 25, 1703-5
Pleomorphic adenoma of the salivary glands: analysis of 94 patients.
Pleomorphic adenoma is a benign epithelial tumor of adenoid structure preferentially arising from the parotid gland. It was shown that complete tumor excision is a curative measure and recurrence is likely in incompletely excised tumors. The aim of this study was to analyse the outcome of patients with pleomorphic adenoma from salivary glands in order to evaluate the surgical strategy of a single institution. The files of 94 patients were evaluated. Special attention was given to the development of malignancy in pleomorphic adenoma. The pleomorphic adenoma preferentially originated in the parotid gland (n=73; right 48, left: 25), and rarely in other glands. The tumor occurred more often in females than in males (45:28, parotid). In 73 patients a slowly growing swelling of the parotid was first noted, which was located at different sites within the gland. At least one recurrence was noted in 18 patients, the majority of them aged 50 to 70 years (n=12). Malignant transformation to carcinoma was found in 8.5%. Pleomorphic adenoma from salivary glands is a benign tumor. However, in a noteworthy number of patients, inside the benign tumor a phenotype develops with distinct properties of malignancy. Surgery with safety margins is the therapy of choice. Multinodular tumors are prone to recurrent disease.
- 22 July 2005
- Vol. 25, 1703-5
Pleomorphic adenoma of the salivary glands: analysis of 94 patients.
Pleomorphic adenoma is a benign epithelial tumor of adenoid structure preferentially arising from the parotid gland. It was shown that complete tumor excision is a curative measure and recurrence is likely in incompletely excised tumors. The aim of this study was to analyse the outcome of patients with pleomorphic adenoma from salivary glands in order to evaluate the surgical strategy of a single institution. The files of 94 patients were evaluated. Special attention was given to the development of malignancy in pleomorphic adenoma. The pleomorphic adenoma preferentially originated in the parotid gland (n=73; right 48, left: 25), and rarely in other glands. The tumor occurred more often in females than in males (45:28, parotid). In 73 patients a slowly growing swelling of the parotid was first noted, which was located at different sites within the gland. At least one recurrence was noted in 18 patients, the majority of them aged 50 to 70 years (n=12). Malignant transformation to carcinoma was found in 8.5%. Pleomorphic adenoma from salivary glands is a benign tumor. However, in a noteworthy number of patients, inside the benign tumor a phenotype develops with distinct properties of malignancy. Surgery with safety margins is the therapy of choice. Multinodular tumors are prone to recurrent disease.
- 22 July 2005
- Vol. 25, 1707-9
Hyperfractionated externally irradiated primary oral squamous cell carcinomas: vital tumor cells in resection specimens.
Oral squamous cell carcinoma (OSCC) is among the most frequent malignancies worldwide. Ablative surgery for OSCC is the therapy of choice, however, severe disfigurement and loss of function is a consequence of therapy. On the other hand, R0-resection margins following ablative surgery do not guarantee disease-free survival, in particular due to the widespread, interconnecting lymphatic vessels. Therefore, irradiation of the primary and efferent lymphatics is a valuable therapeutic alternative to surgery. The combination of both irradiation and surgery might even improve overall survival. It has been argued that curatively planned irradiation (isodose of the primary: 60-70 Gy) might not routinely be followed by ablative surgery. Indeed, the sequelae of surgery in an irradiated field are well known. The aim of this study was to determine vital tumor cells in the resection specimens of irradiated advanced stage OSCC in order to estimate the effect of radiotherapy. One hundred patients (male 78, female: 22, mean age 60.2 years) with primary OSCC (T2: n=41, T3: n=26; T4: n=33) and suspected regional lymph node metastases were externally irradiated up to a total dosage of 70 Gy (single dose 1.4 Gy, twice daily, minimum daily interval 6 hours; 5 days a week). Ablative surgery followed radiotherapy about 3 months later. In 51% of the primaries, specimens showed vital tumor cells after completion of radiotherapy. The evidence of vital tumor cells increased with T-stage and with N-stage, but showed no correlation to grading. Irradiation of the head and neck region following a hyperfractionation scheme for the treatment of advanced stage OSCC offers a 50% chance of deletion of malignant cells. Despite high total dosages and sophisticated irradiation protocols, the number of patients with vital tumor cells is high. Short-term follow-up controls are mandatory in patients who were subjected to a primary radiotherapy. Ablative surgery following irradiation is a salvage option for pre-irradiated OSCC patients.
- 22 July 2005
- Vol. 25, 1707-9
Hyperfractionated externally irradiated primary oral squamous cell carcinomas: vital tumor cells in resection specimens.
Oral squamous cell carcinoma (OSCC) is among the most frequent malignancies worldwide. Ablative surgery for OSCC is the therapy of choice, however, severe disfigurement and loss of function is a consequence of therapy. On the other hand, R0-resection margins following ablative surgery do not guarantee disease-free survival, in particular due to the widespread, interconnecting lymphatic vessels. Therefore, irradiation of the primary and efferent lymphatics is a valuable therapeutic alternative to surgery. The combination of both irradiation and surgery might even improve overall survival. It has been argued that curatively planned irradiation (isodose of the primary: 60-70 Gy) might not routinely be followed by ablative surgery. Indeed, the sequelae of surgery in an irradiated field are well known. The aim of this study was to determine vital tumor cells in the resection specimens of irradiated advanced stage OSCC in order to estimate the effect of radiotherapy. One hundred patients (male 78, female: 22, mean age 60.2 years) with primary OSCC (T2: n=41, T3: n=26; T4: n=33) and suspected regional lymph node metastases were externally irradiated up to a total dosage of 70 Gy (single dose 1.4 Gy, twice daily, minimum daily interval 6 hours; 5 days a week). Ablative surgery followed radiotherapy about 3 months later. In 51% of the primaries, specimens showed vital tumor cells after completion of radiotherapy. The evidence of vital tumor cells increased with T-stage and with N-stage, but showed no correlation to grading. Irradiation of the head and neck region following a hyperfractionation scheme for the treatment of advanced stage OSCC offers a 50% chance of deletion of malignant cells. Despite high total dosages and sophisticated irradiation protocols, the number of patients with vital tumor cells is high. Short-term follow-up controls are mandatory in patients who were subjected to a primary radiotherapy. Ablative surgery following irradiation is a salvage option for pre-irradiated OSCC patients.
- 1 February 2005
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 33 (1) , 55-60
Subtotal and total resection of superficial plexiform neurofibromas of face and neck: four case reports
- 1 February 2005
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 33 (1) , 55-60
Subtotal and total resection of superficial plexiform neurofibromas of face and neck: four case reports
- Open Access
- 31 January 2005
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 3 (1) , 6
Resection of small plexiform neurofibromas in neurofibromatosis type 1 children
Background: Plexiform neurofibromas (PNF) are benign tumors of the peripheral nerve which mostly develop in patients with neurofibromatosis type 1 (NF1). Surgical interventions are usually not applied to children with small tumors. These are rather restricted to debulking of larger tumors in adults that cause clinical complications or aesthetic disfigurement. In most cases, a total resection of PNF is not possible due to the network-like growth of the tumors. Patients and methods: Early surgical intervention was carried out for 9 small PNFs in 7 NF1 children. Tumor resection was performed following the graphical delineation of the affected skin and according the MRI findings. Results: Total resection was achieved for all 9 PNF without causing any neurological or organic deficit. Annual magnetic resonance tomography over a period of four years did not reveal any relapse of the tumors. Conclusions: Early surgical intervention for small superficial PNFs in NF1 children have various advantages and may especially be considered a strategy to prevent progression.
- 31 January 2005
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 3 (1) , 6
Open AccessResection of small plexiform neurofibromas in neurofibromatosis type 1 children
Background: Plexiform neurofibromas (PNF) are benign tumors of the peripheral nerve which mostly develop in patients with neurofibromatosis type 1 (NF1). Surgical interventions are usually not applied to children with small tumors. These are rather restricted to debulking of larger tumors in adults that cause clinical complications or aesthetic disfigurement. In most cases, a total resection of PNF is not possible due to the network-like growth of the tumors. Patients and methods: Early surgical intervention was carried out for 9 small PNFs in 7 NF1 children. Tumor resection was performed following the graphical delineation of the affected skin and according the MRI findings. Results: Total resection was achieved for all 9 PNF without causing any neurological or organic deficit. Annual magnetic resonance tomography over a period of four years did not reveal any relapse of the tumors. Conclusions: Early surgical intervention for small superficial PNFs in NF1 children have various advantages and may especially be considered a strategy to prevent progression.
- Open Access
- 17 May 2004
- Published by Springer Nature in Cancer Cell International
- Vol. 4 (1) , 4
Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients
Malignant peripheral nerve sheath tumors (MPNSTs) are neoplasms leading to death in most cases. Patients with Neurofibromatosis type 1 have an increased risk of developing this malignancy. The metabolites of the inactive prodrug Sulindac, Sulindac Sulfide and Sulindac Sulfone (Exisulind) are new chemopreventive agents that show promising results in the treatment of different cancer types. In this study we examined the antineoplastic effect of these compounds on primary cells derived from two MPNSTs of Neurofibromatosis type 1 patients. Exisulind and Sulindac Sulfide showed a dramatic time- and dose-dependent growth inhibitory effect with IC50-values of 120 μM and 63 μM, respectively. The decrease in viability of the tested cells correlated with induction of apoptosis. Treatment with 500 μM Exisulind and 125 μM Sulindac Sulfide for a period of 2 days increased the rate of apoptosis 21-27-fold compared to untreated cells. Reduced expression of RAS-GTP and phosphorylated ERK1/2 was detected in treated MPNST cells. Moreover, elevated levels of phosphorylated SAPK/JNK were found after drug treatment, and low activation of cleaved caspase-3 was seen. Our results suggest that this class of compounds may be of therapeutic benefit for Neurofibromatosis type 1 patients with MPNST.
- 17 May 2004
- Published by Springer Nature in Cancer Cell International
- Vol. 4 (1) , 4
Open AccessSulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients
Malignant peripheral nerve sheath tumors (MPNSTs) are neoplasms leading to death in most cases. Patients with Neurofibromatosis type 1 have an increased risk of developing this malignancy. The metabolites of the inactive prodrug Sulindac, Sulindac Sulfide and Sulindac Sulfone (Exisulind) are new chemopreventive agents that show promising results in the treatment of different cancer types. In this study we examined the antineoplastic effect of these compounds on primary cells derived from two MPNSTs of Neurofibromatosis type 1 patients. Exisulind and Sulindac Sulfide showed a dramatic time- and dose-dependent growth inhibitory effect with IC50-values of 120 μM and 63 μM, respectively. The decrease in viability of the tested cells correlated with induction of apoptosis. Treatment with 500 μM Exisulind and 125 μM Sulindac Sulfide for a period of 2 days increased the rate of apoptosis 21-27-fold compared to untreated cells. Reduced expression of RAS-GTP and phosphorylated ERK1/2 was detected in treated MPNST cells. Moreover, elevated levels of phosphorylated SAPK/JNK were found after drug treatment, and low activation of cleaved caspase-3 was seen. Our results suggest that this class of compounds may be of therapeutic benefit for Neurofibromatosis type 1 patients with MPNST.